Publications

• M.D. Cappellini, J.B Porter, E. Quebe-Fehling, C. Pallaud, F. Dieterle, Exploring the Clinical Utility of Renal Safety Biomarkers During Iron Chelation Therapy. J. Nephrol. Kidney Dis. 2018 1(2):119-129.

• A. Amberg, B. Riefke, G. Schlotterbeck, A. Ross, H. Senn, F. Dieterle, M. Keck, NMR and MS Methods for Metabolomics, Methods Mol. Biol. 2017 (1641): 229-258.

• M. D. Cappellini, E. Quebe-Fehling, C. Pallaud, F. Dieterle, J.B. Porter, Exploring the Clinical Utility of Renal Safety Biomarkers during Iron Chelation Therapy in Patients with β-Thalassemia and Other Anemias, Blood 2017 (130):4762.

• F. Dieterle, E. Marrer, J. Vonderscher: “Omics Technologies: Promises and Benefits for Molecular Medicine”, “Biomarkers in the context of Health Authorities and Consortia”, “Localization Technologies and Immunoassays: Promises and Benefits for Molecular Medicine” in M. Wehling, Principles of Translational Science in Medicine: From Bench to Bedside 2nd edition, Elsevier, 2015.

• F. Dieterle, E. Marrer “Nephrotoxicity: Development of biomarkers for preclinical and clinical application”; in J. Wang and L. Urban, Predictive ADMET: Integrated Approaches in Drug Discovery and Development, Wiley, 2014.

• F. Dieterle “First-Ever Regulatory Biomarker Qualification - Review and Insights by a Participant” in F. Goodsaid and W. Mattes, The Path from Biomarker Discovery to Regular Qualification, Elsevier, 2013.

• K.A. Matheis, E. Com J.C. Gautier, N. Guerreiro, A. Brandenburg, H.Gmuender, A. Sposny, F. Dieterle, F. Staedtler et al.:  Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers.Toxicol. Appl. Pharmacol. 252 (2011): 112-122.

• J.V. Bonventre, V.S. Vaidya, R. Schmouder, P. Feig, F. Dieterle: Next-generation biomarkers for detecting kidney toxicity. Nature Biotech. 28 (2010):436-440.

• F.D Sistare, F. Dieterle, S. Troth, D.J. Holder, D. Gerhold, D. Andrews-Cleavenger, et al.: Towards consensus practices to qualify safety biomarkers for use in early drug development. Nature Biotech. 28 (2010):446-455.

• F. Dieterle, E. Perentes, A. Cordier, D.R. Roth, P. Verdes, O. Grenet, et al.: Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nature Biotech. 28 (2010):463-469.

• V. S. Vaidya, J.S. Ozer, F. Dieterle, F.B. Collings, V. Ramirez, S. Troth, et al.: Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nature Biotech. 28 (2010):478-85.

• J. S. Ozer, F. Dieterle, S. Troth, E. Perentes, A. Cordier, P. Verdes, et al: A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nature Biotech. 28 (2010):486-94.

• F. Dieterle, F. Sistare, F. Goodsaid, M. Papaluca, J.S. Ozer, C.P. Webb, et al.: Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nature Biotech. 28 (2010):455-462.

• F. Dieterle, B. Riefke, G. Schlotterbeck, A. Ross, H. Senn, A. Amberg: NMR and MS methods for metabonomics. Methods Mol. Biol. 2011 (691):385-415.

• R.K.  Chetty, J.S. Ozer, A. Lanevschi, I. Schuppe-Koistinen, D. McHale, J.S. Pears, J. Vonderscher, F.D. Sistare, F.Dieterle: A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill’s principles of causality association. Clin. Pharmacol. Ther. 88(2010): 260-262.

• F. Dieterle, F. Sistare: Biomarkers in acute kidney injury. In V.S. Vaidya, J.V. Bonventre, Biomarkers in medicine, drug discovery and environmental health, John Wiley and Sons, 2010.

• D. Hoffmann, M. Adler,  V. Vaidya,  E. Rached, L. Mulrane, W.M. Gallagher, J.J. Callanan, J.C. Gautier, K. Matheis, F. Staedtler, F. Dieterle, et al.: Performance of novel kidney biomarkers in preclinical toxicity studies. Tox. Sci. 116 (2010) 8-22.

• F. Dieterle, B. Riefke, G. Schlotterbeck, A. Ross, H. Senn, A. Amberg: NMR and MS methods for metabonomics, in J.-C. Gautier, Drug Safety Evaluation, The Humana Press, 2010.

• E. Marrer E., F.Dieterle: Impact of biomarker development on drug safety assessment. Toxicol. Appl. Pharmacol. 243(2010):167-179.

• F. Dieterle, E. Marrer, J. Vonderscher: “Omics Technologies: Promises and Benefits for Molecular Medicine”, “Biomarkers in the context of Health Authorities and Consortia”, “Localization Technologies and Immunoassays: Promises and Benefits for Molecular Medicine” in M. Wehling, Principles of Translational Science in Medicine: From Bench to Bedside, Cambridge University Press, 2010.

• F.M. Goodsaid, M.  Blank, F. Dieterle, P. Harlow, E. Hausner, F. Sistare, A. Thompson, J. Vonderscher: Novel Biomarkers of Acute Kidney Toxicity. Clin. Pharmacol. Ther. 86 (2009) 490-496.

• P. Mueller, F. Dieterle: Tissue-Specific, Non-Invasive Toxicity Biomarkers: Translation from Preclinical Safety Assessment to Clinical Safety Monitoring, Expert Opin. Drug Metab. Toxicol., 5 (2009) 1023-1038.

• F. Sistare, P. Dejavaran, M. Blank, J. Bonventre, F. Dieterle, R. Star, D. Warnock: Assessing and Predicting Kidney Safety. In Steve Olson, Sally Robinson, and Robert Giffin: Accelerating the Development of Biomarkers for Drug Safety, The National Academic Press, 2009.

• F. Dieterle, E. Marrer, E. Suzuki, O. Grenet, A. Cordier, J. Vonderscher: Monitoring kidney safety in drug development: Emerging technologies and their implications, Cur. Opin. Drug. Disc. Devel. 11 (2008) 60-71.

• E. Marrer, F. Dieterle: Biomarkers in oncology drug development: rescuers or troublemakers, Expert Opin. Drug Metab. Toxicol. 4 (2008) 1391-1402.

• F. Dieterle, E. Marrer: New technologies around biomarkers and their interplay with drug development, Anal. Bioanal. Chem. 390 (2008) 141-154.

• F. Dieterle, G. Schlotterbeck, A. Binder, A. Ross, L. Suter, H. Senn: Application of metabonomics in a comparative profiling study reveals N-acetyl-felinine excretion as biomarker for inhibition of the farnesyl pathway by bisphosphonates, Chem. Res. Toxicol., 20 (2007) 1291-1299.

• G. Schlotterbeck, F. Dieterle, A. Ross, H. Senn: Metabolic Profiling in Pharmaceutical Drug Discovery – Robust and Automated Analysis of Metabonomic Data Sets, Chimia, 61 (2007) 671.

• E. Marrer, F. Dieterle: Promises of biomarkers in drug development – a reality check, Chem. Biol. Drug Design, 69 (2007): 381-394.

• A. Ross, G. Schlotterbeck, F. Dieterle, H. Senn: NMR spectroscopy techniques for application to metabonomics, in J.C. Lindon, J.K. Nicholson, E. Holmes, The Handbook of Metabonomics and Metabolomics, Elsevier, Amsterdam, 2007.

• G. Schlotterbeck, A. Ross, H. Senn, F. Dieterle: Metabolic profiling technologies for biomarker discovery in biomedicine and drug development, Pharmacogenomics, 7 (2006): 1055-1075.

• F. Dieterle, A. Ross, G. Schlotterbeck, U.  Niederhauser, H. Senn: Application of metabonomics in a compound ranking study in early drug development revealing drug-induced excretion of choline into urine, Chem. Res. Toxicol., 19 (2006) 1175-1181.

• F. Dieterle, A. Ross, G. Schlotterbeck, H. Senn: Metabolite projection analysis for fast identification of metabolites in metabonomics - application in an amiodarone study, Anal. Chem., 78 (2006): 3551-3561.

• F. Dieterle, A. Ross, G. Schlotterbeck, H. Senn: Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures - application in 1H-NMR metabonomics, Anal. Chem., 78 (2006): 4281-4290.

• F. Dieterle: Time-resolution of sensors for multi-analyte determinations, in C.A. Grimes, E.C. Dickey, M.V. Pishko: Encyclopedia of Sensors, American Scientific Publishers, Stevenson Ranch, California, 2006.

• F. Dieterle, S. Busche, G. Gauglitz: Different approaches for a multivariate calibration of nonlinear sensor data – a review, Anal. Bioanal. Chem., 380 (2004): 383-369.

• F. Dieterle: Time-resolved sensor arrays, Anal. Bioanal. Chem., 378 (2004): 66-67.

• M. Kasper, S. Busche, F. Dieterle, G. Gauglitz: Quantification of quaternary mixtures of alcohols: a comparison of reflectometric interference spectroscopy and surface plasmon resonance spectroscopy, Meas. Science Technol., 15 (2004): 540-548.

• F. Dieterle, S. Müller-Hagedorn, H.M. Liebich, G. Gauglitz: Urinary nucleosides as potential tumor markers evaluated by learning vector quantization, Artif. Intell. Med., 28 (2003): 265-279.

• F. Dieterle, B. Kieser, G. Gauglitz: Genetic algorithms and neural networks for the quantitative analysis of ternary mixtures using a single sensor set-up, Chemometr. Intell. Lab. Syst., 65 (2003): 67-81.

• S. Busche, F. Dieterle, B. Kieser, G. Gauglitz: Quantification of binary mixtures of the freones R22 and R134a by surface plasmon resonance, Sens. Actuators. B, 89 (2003): 192-198.

• F. Dieterle, S. Busche, G. Gauglitz: Growing neural networks for a multivariate calibration and variable selection of time-resolved measurements, Anal. Chim. Acta, 490 (2003): 71-83.

• Reder, F. Dieterle, H. Jansen, S. Alcock, G. Gauglitz: Multi-analyte assays for triazines using cross-reactive antibodies and neural networks, Biosens. Bioelectron., 19 (2003): 447-455.

• F. Dieterle, S. Reder, G. Gauglitz: Kreuzreaktivität – Ein Nachteil wird zum Vorteil für die Biosensorik, Technisches Messen, 70 (2003): 569-573.

• B. Kieser, F. Dieterle, G. Gauglitz: Discrimination of methanol and ethanol vapors by the use of a single optical sensor with a microporous sensitive layer. Anal Chem. 2002 74(18): 4781-4787.

• F. Dieterle, G. Belge, C. Betsch, G. Gauglitz: Quantification of the refrigerants R22 and R134a in mixtures by means of different polymers and reflectometric interference spectroscopy, Anal. Bioanal. Chem., 371 (2002): 858-867.

• F. Dieterle, D. Nopper, G. Gauglitz: Quantification of butanol and ethanol in aqueous phases by reflectometric interference spectroscopy – different approaches to multivariate calibration, Fresenius J. Anal. Chem., 370 (2001): 723-730.

Patents

• F. Dieterle, H. Hoefling, Acute Kidney Injury, patent 2015

• F. Dieterle, G. Maurer, E. Perentes, A. Cordier, F. Legay, O. Grenet, P. Grass, D.R. Roth, D. Wahl, F. Staedtler, J. Vonderscher, S.D. Chibout: Predictive renal safety biomarkers and biomarker signatures to monitor kidney function, patent 2007.

• F. Dieterle, A. Ross, G. Schlotterbeck, L. Suter-Dick, H. Senn: Biomarker for farnesyl pathway, patent 2006.

• F. Dieterle, A. Ross, G. Schlotterbeck, H. Senn: Method for processing a set of spectra, particularly NMR spectra, patent 2005.